 NEW HAVEN, Conn., Nov. 10, 2020 GLOBE NEWSWIRE -- Trevi Therapeutics, Inc. Nasdaq: TRVI, a clinical-stage biopharmaceutical company focused on the development and commercialization of HaduvioTM nalbuphine ER to treat serious neurologically mediated conditions, today announced that management will present a Company overview, as well as host virtual investor meetings, at the Stifel 2020 Virtual Healthcare Conference on November 17, 2020. 